Inhibitor Therapeutics

(OTC) INTI

Current Price$0.09

Market Cap$15.53M

Since IPO (1997)-99%

5 Year+44%

1 Year+83%

1 Month+3%

Inhibitor Therapeutics Financials at a Glance

Market Cap

$15.53M

Revenue (TTM)

$0.00

Net Income (TTM)

$3.30M

EPS (TTM)

$-0.02

P/E Ratio

-4.71

Dividend

$0.00

Beta (Volatility)

-0.26 (Low)

Dividend

$0.00

Beta (Volatility)

-0.26 (Low)

Price

$0.09

Volume

7,500

Open

$0.09

Price

$0.09

Volume

7,500

Open

$0.09

Previous Close

$0.09

Daily Range

$0.09 - $0.09

52-Week Range

$0.03 - $0.12

Dividend

$0.00

Beta (Volatility)

-0.26 (Low)

Price

$0.09

Volume

7,500

Open

$0.09

Previous Close

$0.09

Daily Range

$0.09 - $0.09

52-Week Range

$0.03 - $0.12

INTI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Inhibitor Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Frank E. O'Donnell, Jr.

Website

www.inhibitortx.com

Headquarters

Tampa, FL 33602, US

INTI Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-952%

Return on Capital

-2%

Return on Assets

-1%

Earnings Yield

-21.23%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$15.53M

Shares Outstanding

172.57M

Volume

7.50K

Avg. Volume

20.16K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$3.43M

EBITDA

$3.43M

Operating Cash Flow

$3.23M

Capital Expenditure

$0.00

Free Cash Flow

$3.23M

Cash & ST Invst.

$2.38M

Total Debt

$61.61K

Inhibitor Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$15.53M

N/A

Market Cap/Employee

$5.18M

N/A

Employees

N/A

Net Income

$1.30M

+8.9%

EBITDA

$1.32M

+7.5%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$2.31M

-58.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$36.89K

N/A

Short Term Debt

$24.72K

N/A

Return on Assets

-1.31%

N/A

Return on Invested Capital

-1.96%

N/A

Free Cash Flow

$601.16K

+22.1%

Operating Cash Flow

$601.16K

+22.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

LIANYLianBio

LIANYLianBio$0.12+0.00%

BETRFBetterLife Pharma Inc.

BETRFBetterLife Pharma Inc.$0.05+6.25%

CUBTCurative Biotechnology, Inc.

CUBTCurative Biotechnology, Inc.$0.95+1.33%

NYMXFNymox Pharmaceutical Corporation

NYMXFNymox Pharmaceutical Corporation$0.07+9.83%

PHRRFPharmaTher Holdings Ltd.

PHRRFPharmaTher Holdings Ltd.$0.06+1.64%

NSVGFNass Valley Gateway Ltd.

NSVGFNass Valley Gateway Ltd.$0.01+0.00%

DVHGFDevonian Health Group Inc.

DVHGFDevonian Health Group Inc.$10.65+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$13.30+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.07+0.05%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.70+0.01%

SOFISoFi Technologies

SOFISoFi Technologies$16.43+0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$65.30+0.03%

NIONio

NIONio$5.91-0.08%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$50.22-0.03%

Questions About INTI

What is the current price of Inhibitor Therapeutics?

Inhibitor Therapeutics is trading at $0.09 per share.

What is the 52-week range for Inhibitor Therapeutics?

Over the past 52 weeks, Inhibitor Therapeutics has traded between $0.03 and $0.12.

How much debt does Inhibitor Therapeutics have?

As of the most recent reporting period, Inhibitor Therapeutics reported total debt of $61,613.

How much cash does Inhibitor Therapeutics have on hand?

Inhibitor Therapeutics reported $2.38M in cash and cash equivalents in its most recent financial results.

What is Inhibitor Therapeutics’s dividend yield?

Inhibitor Therapeutics does not currently have a dividend yield.

Inhibitor Therapeutics

Inhibitor Therapeutics Financials at a Glance

INTI News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Inhibitor Therapeutics

INTI Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Inhibitor Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About INTI

What is the current price of Inhibitor Therapeutics?

What is the 52-week range for Inhibitor Therapeutics?

How much debt does Inhibitor Therapeutics have?

How much cash does Inhibitor Therapeutics have on hand?

What is Inhibitor Therapeutics’s dividend yield?

Premium Investing Services